Anacor Announces Positive Results From Phase 2 Trial Of Novel Anti-Inflammatory Agent For The Treatment Of Atopic Dermatitis
Fri, 16 Jun 2006 06:00 AM EST
... Anacor Pharmaceuticals, aprivately-held pharmaceutical company developing novel agents forinflammatory and infectious diseases, today announced promising data from aPhase 2a study of AN0128, a novel topical anti-inflammatory drug candidatefor atopic dermatitis (AD), a disease affecting approximately 15 millionAmericans. [click link for full article] ...
Related Topics
- Atopic Dermatitis
- Clinical Trials
- Dermatitis
- Agent Orange
- Chemical Agents
- Inflammatory Bowel Disease
- Dermatitis-Atopic Eczema
- Pelvic Inflammatory Disease
- Wrinkles
- Anti-Inflammatory Diets
- Anti-inflammatory Medications
- Eczema
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Aging Skin
- Aging
- Tb
- Virus
- Chronic Inflammatory Demyelinating Polyneuropathy
- Crohn's Disease
- Fatigue

Not Signed In -


